{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T21:59:23Z","timestamp":1721080763024},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BMBF GO-Bio","award":["0315562"],"award-info":[{"award-number":["0315562"]}]},{"name":"International Graduate School Ulm (IGradU, Excellence Initiative of the German Federal and State Governments)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0176852","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T18:11:03Z","timestamp":1493921463000},"page":"e0176852","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Covalent decoration of adenovirus vector capsids with the carbohydrate epitope \u03b1Gal does not improve vector immunogenicity, but allows to study the in vivo fate of adenovirus immunocomplexes"],"prefix":"10.1371","volume":"12","author":[{"given":"Ramona F.","family":"Kratzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrid","family":"Espenlaub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias W.","family":"Kron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kreppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,5,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"N Tatsis","year":"2004","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"MO Lasaro","year":"2009","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1128\/JVI.72.5.4212-4223.1998","article-title":"Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers","volume":"72","author":"K Jooss","year":"1998","journal-title":"J Virol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1182\/blood-2002-07-2146","article-title":"Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells","volume":"101","author":"BR De Geest","year":"2003","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1016\/j.vaccine.2011.06.071","article-title":"Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8\u03b1+ dendritic cell subset","volume":"29","author":"M Suleman","year":"2011","journal-title":"Vaccine"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.1016\/j.vaccine.2010.08.068","article-title":"Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1","volume":"28","author":"AD Douglas","year":"2010","journal-title":"Vaccine"},{"key":"ref7","first-page":"2602","article-title":"The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus","volume":"187","author":"SC de Cassan","year":"2011","journal-title":"J Immunol Baltim Md 1950"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/sj.gt.3302232","article-title":"T-cell response to adenovirus hexon and DNA-binding protein in mice","volume":"11","author":"T McKelvey","year":"2004","journal-title":"Gene Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1128\/JVI.76.1.127-135.2002","article-title":"Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response","volume":"76","author":"V Molinier-Frenkel","year":"2002","journal-title":"J Virol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jconrel.2012.02.007","article-title":"Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells","volume":"160","author":"WWJ Unger","year":"2012","journal-title":"J Control Release Off J Control Release Soc"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1002\/eji.201343429","article-title":"In vivo targeting of human DC-SIGN drastically enhances CD8<sup>+<\/sup> T-cell-mediated protective immunity","volume":"43","author":"C Hesse","year":"2013","journal-title":"Eur J Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/jgm.1112","article-title":"Enhanced transduction of dendritic cells by FcgammaRI-targeted adenovirus vectors","volume":"9","author":"R Sapinoro","year":"2007","journal-title":"J Gene Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/S0264-410X(03)00050-1","article-title":"CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation","volume":"21","author":"JG Brand\u00e3o","year":"2003","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"6943","DOI":"10.1128\/JVI.00310-06","article-title":"Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes","volume":"80","author":"U Abdel-Motal","year":"2006","journal-title":"J Virol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.vaccine.2009.12.015","article-title":"Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120\/p24 fusion protein vaccine expressing alpha-gal epitopes","volume":"28","author":"UM Abdel-Motal","year":"2010","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1016\/j.vaccine.2009.03.019","article-title":"Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody","volume":"27","author":"UM Abdel-Motal","year":"2009","journal-title":"Vaccine"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"9131","DOI":"10.1128\/JVI.00647-07","article-title":"Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells","volume":"81","author":"UM Abdel-Motal","year":"2007","journal-title":"J Virol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/sj.cgt.7700812","article-title":"In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene","volume":"12","author":"L Deriy","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00007890-199601150-00004","article-title":"The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation","volume":"61","author":"RG Tearle","year":"1996","journal-title":"Transplantation"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"17755","DOI":"10.1016\/S0021-9258(19)77900-9","article-title":"Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells","volume":"263","author":"U Galili","year":"1988","journal-title":"J Biol Chem"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1084\/jem.160.5.1519","article-title":"A unique natural human IgG antibody with anti-alpha-galactosyl specificity","volume":"160","author":"U Galili","year":"1984","journal-title":"J Exp Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/00007890-199804150-00018","article-title":"Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type II activation","volume":"65","author":"A Palmetshofer","year":"1998","journal-title":"Transplantation"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1126\/science.1078942","article-title":"Production of alpha 1,3-galactosyltransferase-deficient pigs","volume":"299","author":"CJ Phelps","year":"2003","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nbt0302-251","article-title":"Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs","volume":"20","author":"Y Dai","year":"2002","journal-title":"Nat Biotechnol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.1016\/S0021-9258(19)39258-0","article-title":"Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:beta-D-Gal(1,4)-D-GlcNAc alpha(1,3)-galactosyltransferase cDNA","volume":"265","author":"RD Larsen","year":"1990","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1073\/pnas.84.5.1369","article-title":"Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates","volume":"84","author":"U Galili","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref27","article-title":"Subcellular Biochemistry, a-Gal and Anti-Gal","author":"U Galili","year":"1999"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1073\/pnas.88.16.7401","article-title":"Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys","volume":"88","author":"U Galili","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1182\/blood.V82.8.2485.2485","article-title":"One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody","volume":"82","author":"U Galili","year":"1993","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/IAI.56.7.1730-1737.1988","article-title":"Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora","volume":"56","author":"U Galili","year":"1988","journal-title":"Infect Immun"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/00007890-199804270-00020","article-title":"A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody","volume":"65","author":"U Galili","year":"1998","journal-title":"Transplantation"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/00007890-199809270-00010","article-title":"A murine model of antibody-mediated hyperacute rejection by galactose-alpha(1,3)galactose antibodies in Gal o\/o mice","volume":"66","author":"IF McKenzie","year":"1998","journal-title":"Transplantation"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1097\/00007890-200006270-00020","article-title":"Anti-Gal antibodies in humans and 1, 3alpha-galactosyltransferase knock-out mice","volume":"69","author":"TR Chiang","year":"2000","journal-title":"Transplantation"},{"issue":"Pt 2","key":"ref34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1099\/0022-1317-70-2-429","article-title":"Use of human adenovirus-based vectors for antigen expression in animals","volume":"70","author":"L Prevec","year":"1989","journal-title":"J Gen Virol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine","volume":"5","author":"G Gray","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/infdis\/jis342","article-title":"Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)","volume":"206","author":"A Duerr","year":"2012","journal-title":"J Infect Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/QAD.0b013e328342115c","article-title":"Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study","volume":"25","author":"ME Curlin","year":"2011","journal-title":"AIDS Lond Engl"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CDLI.11.2.351-357.2004","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"E Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/jmv.23325","article-title":"Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China","volume":"84","author":"B Yu","year":"2012","journal-title":"J Med Virol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"TC Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1086\/314498","article-title":"Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey","volume":"178","author":"SL Ludwig","year":"1998","journal-title":"J Infect Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jconrel.2016.06.022","article-title":"Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity","volume":"235","author":"L Krutzke","year":"2016","journal-title":"J Control Release Off J Control Release Soc"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/mt.2010.229","article-title":"Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells","volume":"19","author":"J-M Prill","year":"2011","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ymthe.2005.03.006","article-title":"Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors","volume":"12","author":"F Kreppel","year":"2005","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1089\/104303400750001417","article-title":"Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production","volume":"11","author":"G Schiedner","year":"2000","journal-title":"Hum Gene Ther"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1089\/104303402320138934","article-title":"A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations","volume":"13","author":"F Kreppel","year":"2002","journal-title":"Hum Gene Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/mt.2008.141","article-title":"The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens","volume":"16","author":"R Schirmbeck","year":"2008","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/mp100214b","article-title":"Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach","volume":"8","author":"QL Matthews","year":"2011","journal-title":"Mol Pharm"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e0154819","DOI":"10.1371\/journal.pone.0154819","article-title":"A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine","volume":"11","author":"JA Fonseca","year":"2016","journal-title":"PloS One"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e11815","DOI":"10.1371\/journal.pone.0011815","article-title":"HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach","volume":"5","author":"QL Matthews","year":"2010","journal-title":"PloS One"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"19940","DOI":"10.1073\/pnas.0907898106","article-title":"Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1","volume":"106","author":"A Benlahrech","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nm.1989","article-title":"Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells","volume":"15","author":"NA Hutnick","year":"2009","journal-title":"Nat Med"},{"key":"ref53","first-page":"1","article-title":"Beneficial modification of the endotoxin molecule","volume":"3","author":"E Ribi","year":"1984","journal-title":"J Biol Response Mod"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1016\/j.vaccine.2007.07.026","article-title":"Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant","volume":"25","author":"MG Chaitra","year":"2007","journal-title":"Vaccine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0176852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T06:45:29Z","timestamp":1658990729000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0176852"}},"subtitle":[],"editor":[{"given":"Ilya","family":"Ulasov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,4]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0176852","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,4]]}}}